HER2-Positive Cancer Treatment Evolution Evaluated
Researchers have analyzed how new study designs in gastroesophageal cancer treatment compare to established standards.
Updated on Sept. 30, 2026 in Cancer
Clinical experts have assessed the shifting landscape for treating HER2-positive gastroesophageal adenocarcinoma (GEA). The discussion centers on whether newer combination therapies outperform the long-standing standard of care.
Why it matters
Understanding how treatment protocols evolve is critical for patients navigating options, as trial designs impact whether new therapies reflect the current clinical standard. This evaluation highlights the complex process of refining treatment regimens for aggressive gastrointestinal cancers.
The HERIZON-GEA-01 trial evaluated zanidatamab plus chemotherapy against a control arm of trastuzumab plus chemotherapy. While the trial design addressed progression-free and overall survival, its reliance on a control arm without immunotherapy reflects a design period preceding current standards.
The players
Moffitt Cancer Center
A major research institution that provides comprehensive cancer care and is home to lead physicians evaluating gastrointestinal malignancy treatment.
University of Colorado Cancer Center
A collaborative oncology center involved in clinical research and the advancement of complex treatment regimens for esophageal and gastric cancers.
The details
HER2-positive GEA treatment historically relied on trastuzumab combined with chemotherapy, as established by the ToGA trial. Recent shifts, specifically the KEYNOTE-811 trial, introduced pembrolizumab, though clinical benefits are primarily limited to patients with PD-L1-positive tumors. The HERIZON-GEA-01 study explored the efficacy of zanidatamab, a bispecific antibody, compared against the older trastuzumab standard, illustrating the challenge of comparing new therapies against rapidly changing baselines.
Timeline
On September 30, 2026, experts discussed the evolution of GEA treatment protocols.
Health Landscape
The landscape of HER2-positive GEA care is transitioning from single-agent targeted therapy to more complex combinations involving immunotherapy. This analysis highlights how historical trial designs must be interpreted carefully in light of the standard set by the KEYNOTE-811 trial.
Patients diagnosed with HER2-positive GEA should discuss with their oncology team how current treatment regimens align with the latest clinical evidence, particularly concerning the inclusion of immunotherapy. It is important to ask whether a specific treatment protocol relies on the current standard of care.
The takeaway
Treatment strategies for HER2-positive GEA are shifting toward combination approaches, making it essential to understand the foundation of any recommended regimen. Always ask your specialist how your specific treatment plan compares to the latest validated standards of care for your diagnosis.
Further reading
For more on the current research and emerging treatment protocols for gastrointestinal malignancies, visit Cancer.
Source note: This article includes information reported by OncLive.
